OCT

Contract Research Organization Servicesoct-clinicaltrials.com

Company typePrivate
Founded2005
HeadquartersHamburg, Germany
Headcount101–250
GTM typeB2B
OfferingServices

OCT firmographics

Firmographics

Name: OCT
Legal name: OCT Group LLC
Website: https://oct-clinicaltrials.com
Company type: Private
Founded year: 2005
Operating status: Operating
Headcount range: 101–250 employees
Ownership category
akta.pro rank

OCT industry classification

Industry

Product category: Contract Research Organization Services
NAICS: Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
SIC: Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro primary industry: Clinical CROs (Phase I–IV) (HLAGAAAA)
akta.pro secondary industries: Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

Clinical trial services
Contract research organization
Biostatistics and data management
Pharmacovigilance services
Regulatory consulting

Where OCT is headquartered

Location

Headquarters

HQ city: Hamburg
HQ country: Germany
HQ region: Europe

Offices11 records

Markets served

OCT business model

Business model

GTM type: B2B
Offering type: Services
Cost components: Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

Full-Service Clinical Trial Management: Comprehensive Phase I-IV and BE clinical trial services including project management, monitoring, data management, biostatistics, regulatory support, and drug safety. Charges on a per-study, per-service basis.
Standalone/Partial Services: Individual clinical development services offered separately including specific therapeutic area expertise, site management, feasibility studies, and specialized consulting.

Pricing tiers

Model	Billing	Price
Other	Multi-year contract	Custom project-based pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

OCT product offering

Product offering

Core offering

OCT is a full-service Contract Research Organization (CRO) that conducts Phase I–IV clinical trials and bioequivalence studies, primarily across Eastern Europe and CIS countries. The company delivers end-to-end clinical research services including study design, regulatory and marketing-authorization support, project management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, and clinical supply logistics. OCT also offers dedicated oncology solutions (OCT Oncology™), rescue studies for stalled trials, and a free feasibility report as a pre-engagement offering.

Product overview

OCT is a full-service Clinical Research Organization (CRO) providing comprehensive clinical trial services for Phase I-IV and BE (bioequivalence) studies. The company offers both full-service clinical study engagements and standalone services across 21 countries with access to 2,100 leading research sites. The core service portfolio includes Clinical Study Design Preparation, MedSci Consulting and Excellence™, Consulting and Regulatory Support, Drug Safety and Pharmacovigilance, Project Management and Monitoring, Clinical Data Management, Biostatistics, Clinical Supply Services and Logistics, Medical Writing, and Marketing Authorization Support. The company also offers specialized service packages including OCT Oncology™ for dedicated oncology solutions and Rescue Studies for troubled clinical trials. Since 2005, OCT has conducted over 300 studies across 29 therapeutic areas including Oncology, Gastroenterology, Rheumatology, Neurology, Infectious Diseases, and Respiratory Diseases.

Differentiator

Problem solved

Functional benefit

Brands

OCT Oncology™: A dedicated solutions package aimed at helping pharma from early to late stage oncology treatment development. Includes access to 300 leading oncology clinics in 10 countries and specialized immuno-oncology study expertise.

Products and services

Phase I–IV Clinical Trial Management End-to-end management of Phase I, II, III, and IV clinical trials, including site activation, patient enrollment, monitoring, and closeout, primarily across Eastern Europe and CIS countries.
Bioequivalence Studies Bioequivalence study services to support generic and biosimilar development programs for pharmaceutical sponsors.
Rescue Studies Specialized services to take over, re-energize, and complete stalled or under-enrolling clinical trials transferred from other CROs or sponsors.
OCT Oncology™ Dedicated oncology clinical trial services with specialized protocol design, oncology-experienced sites, and an oncology-focused operations unit, covering 80+ oncology studies and 35,466 oncology patients.
MedSci Consulting and Excellence™ Scientific and medical consulting services to support clinical development strategy, protocol design, and study planning for pharmaceutical and biotech sponsors.
Regulatory and Marketing Authorization Support Regulatory affairs consulting and marketing authorization application support for EMA, FDA, and regional Eastern European/CIS submissions.
Drug Safety and Pharmacovigilance
Biostatistics and Data Management
Medical Writing
Clinical Supply Services and Logistics
Free Feasibility Report

Quantifiable outcome

Up to 4x faster enrollment rates compared to other regions
+3 more outcomes

Companies that use OCT

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

OCT technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

OCT partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

EUCROF (European CRO Federation)moderateStrategic or Co-development PartnerOCT is an official member of the European CRO Federation, an industry organization representing clinical research organizations across Europe. This membership provides access to industry best practices, regulatory updates, and networking within the European clinical research community.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

OCT competitors and assessment

Company assessment

Broad incumbents

Medpace Holdings: Mid-to-large CRO with strong oncology franchise and full-service Phase I-IV delivery. Comparable therapeutic mix though larger and US-centric.
Parexel International: Large global CRO with full Phase I-IV services and significant biopharma client base. Competes for enterprise study awards where OCT also bids.
ICON plc: Top-3 global CRO offering full-service clinical development across all phases and geographies. Represents the most direct large-scale competitor for Eastern European Phase II/III awards.
IQVIA: Largest global CRO with extensive technology stack and broad sponsor relationships. Sets the competitive ceiling for mid-size CROs competing for global Phase III work.
Syneos Health: Global biopharma solutions organization combining CRO and commercial services. Competes for full-service clinical work across multiple therapeutic areas.

Direct peers

Worldwide Clinical Trials: Mid-size global CRO offering Phase I-IV services with therapeutic area depth including oncology and CNS. Similar size tier and full-service positioning.
PSI CRO: Switzerland-based mid-size CRO with deep Central and Eastern European site network and full-service Phase I-IV capabilities. Highly comparable operating model and regional positioning.
Ergomed plc: UK-headquartered mid-size CRO with strong Central and Eastern European footprint and oncology specialization. Closely comparable in size, geographic focus, and service mix.

Emerging players

Clinipace Worldwide: Smaller mid-size CRO offering full-service clinical development with therapeutic focus areas. Comparable size tier and service model to OCT.
Catalyst Clinical Research: Mid-size oncology-focused CRO with similar therapeutic concentration. Comparable as an oncology-specialized competitor for biotech Phase II/III work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

OCT compliance and trust

Trust signal

Compliance2 records

OCT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OCT leadership team

Management profile

Number of profiles

Profiles4 records

OCT funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OCT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCT

What does OCT do?

Is OCT a public or private company?

OCT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OCT founded?

OCT was founded in 2005. It employs 101 to 250 people.

Where is OCT based?

OCT is headquartered in Hamburg, Germany, in the Europe region.

How does OCT make money?

Two revenue lines are on record. Full-Service Clinical Trial Management is the primary driver. The others are standalone/Partial Services.

Who are OCT's main competitors?

Broad incumbents on record are Medpace Holdings, Parexel International, ICON plc, IQVIA and Syneos Health. Direct peers are Worldwide Clinical Trials, PSI CRO and Ergomed plc. Emerging players are Clinipace Worldwide and Catalyst Clinical Research.

Does OCT have an API?

No public API is recorded for OCT.

What industry is OCT in?

OCT's product category is Contract Research Organization Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.